Hospices Civils de Lyon: Leukemia, Myeloid trials

The registry lists 14 Leukemia, Myeloid studies with Hospices Civils de Lyon as lead sponsor. 1 are open to participants now and 0 have results posted.

Phase 2 2No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Role of BMP Pathway in MDS ProgressionNot yet recruitingNCT06175923
• Assessing Refractoriness and Infectious Survival Events in AMLCompletedNCT06709235
• Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/RefractoryCompletedNCT06429670
• Endogenous Retroviruses in Acute Myeloid LeukemiaWithdrawnNCT04406207
• Study of the Outcome of Patients With Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Receiving Iron Chelation Therapy After Allogeneic Hematopoietic Stem Cell TransplantationStatus unknownNCT03659084
• Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.CompletedNCT03350152
• Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid LeukemiaCompletedNCT03234985
• Transfusion in Adult Acute Myeloid LeukemiaCompletedNCT02899767
• Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the ElderlyCompletedNCT02845232
• Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid LeukaemiaCompletedNCT02844257
• Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid LeukemiaCompletedNCT02844218
• Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid LeukemiaCompletedNCT02842112
• Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT01294618Phase 2
• AFR10 - Combination Therapy of Imatinib Mesylate (IM) + Alpha-2A Interferon for Chronic Phase CML Patients Resistant or Refractory to IM Used as Single Therapy for at Least One YearStatus unknownNCT00146913Phase 2